Alimera Sciences (NASDAQ:ALIM) Lifted to “Buy” at upgraded shares of Alimera Sciences (NASDAQ:ALIMFree Report) from a hold rating to a buy rating in a report released on Monday morning.

Separately, Maxim Group assumed coverage on shares of Alimera Sciences in a report on Monday, March 25th. They issued a buy rating and a $10.00 target price for the company.

Get Our Latest Research Report on ALIM

Alimera Sciences Stock Performance

Shares of ALIM opened at $3.63 on Monday. The firm’s 50 day moving average is $3.71 and its 200-day moving average is $3.63. The stock has a market capitalization of $190.03 million, a P/E ratio of -1.68 and a beta of 1.18. The company has a debt-to-equity ratio of 1.40, a current ratio of 2.39 and a quick ratio of 2.31. Alimera Sciences has a 12-month low of $1.56 and a 12-month high of $4.38.

Alimera Sciences (NASDAQ:ALIMGet Free Report) last announced its earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.09). Alimera Sciences had a negative return on equity of 130.90% and a negative net margin of 24.93%. The firm had revenue of $26.31 million during the quarter, compared to analyst estimates of $25.10 million. During the same quarter in the previous year, the business earned ($0.54) earnings per share. Equities research analysts anticipate that Alimera Sciences will post 0.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Alimera Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Stonepine Capital Management LLC grew its holdings in shares of Alimera Sciences by 0.4% during the 4th quarter. Stonepine Capital Management LLC now owns 3,999,459 shares of the biopharmaceutical company’s stock valued at $17,278,000 after acquiring an additional 15,773 shares in the last quarter. Worth Venture Partners LLC purchased a new position in shares of Alimera Sciences during the 3rd quarter valued at $1,840,000. Finally, AIGH Capital Management LLC purchased a new position in shares of Alimera Sciences during the 3rd quarter valued at $7,355,000. Hedge funds and other institutional investors own 99.83% of the company’s stock.

Alimera Sciences Company Profile

(Get Free Report)

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).

Read More

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with's FREE daily email newsletter.